Biopharma AI
By
China focus: Is AstraZeneca’s $5.3B AI-Powered Alliance with CSPC the New Gold Standard in Chronic Disease Drug Discovery?
Key Takeaways: AI as the Catalyst: CSPC’s Dual-Engine Platform Front and CenterAt the core of this partnership lies…
How Tempus AI and Northwestern Use AI to Unlock the Genomic Code of Alzheimer’s? A New Collaboration Targets Precision Breakthroughs
Key Takeaways Transforming Alzheimer’s Research with AI and Precision GenomicsIn a multi-year collaboration announced today, Tempus AI (NASDAQ:…
Can Parallel Bio’s $21M Bet on Immune Organoids Cut Drug Failure Rates from 95% to 5%?
Key Highlights Organoid-AI Platform Aims to Transform Preclinical Drug DiscoveryParallel Bio’s proprietary platform replicates the human immune system…
Can BullFrog AI and Sygnature Discovery’s $30M Alliance Reshape How Global Biopharma Uses AI in Drug Discovery?
Key Highlights BullFrog AI Secures Global CRO Partner to Scale AI PlatformBullFrog AI has entered a commercial collaboration…
At VivaTech 2025, Can NVIDIA, Sanofi, and TetraScience Unlock the Full Potential of Scientific AI Despite a 20-Exabyte Data Barrier?
Key Highlights The 20-Exabyte Problem: Data, Not Models, Is the Limiting FactorAt The Rise of Scientific AI panel…
Is AstraZeneca’s $20M AI Hub in Bengaluru the Catalyst for 20 New Medicines by 2030?
Key Highlights Strategic Investment to Scale AI-Driven InnovationAstraZeneca has inaugurated a state-of-the-art Global Hub in Bengaluru with an…
